456 related articles for article (PubMed ID: 18662281)
21. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension.
Manolakopoulos S; Triantos C; Theodoropoulos J; Vlachogiannakos J; Kougioumtzan A; Papatheodoridis G; Tzourmakliotis D; Karamanolis D; Burroughs AK; Archimandritis A; Raptis S; Avgerinos A
J Hepatol; 2009 Sep; 51(3):468-74. PubMed ID: 19616339
[TBL] [Abstract][Full Text] [Related]
22. [Prevention and treatment of hepatitis B virus reinfection after liver transplantation].
Liu J; Wu GC; Zhang ZT; Wu P; Zhang D; Sun MC; Gao DC; Wang Y; Jia JD; Wang BE
Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):976-9. PubMed ID: 16194352
[TBL] [Abstract][Full Text] [Related]
23. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.
Eun JR; Lee HJ; Kim TN; Lee KS
J Hepatol; 2010 Jul; 53(1):118-25. PubMed ID: 20471129
[TBL] [Abstract][Full Text] [Related]
24. Early mortality in Taiwanese lamivudine-treated patients with chronic hepatitis B-related decompensation: evaluation of the model for end-stage liver disease and index scoring systems as prognostic predictors.
Dai CY; Chuang WL; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Huang JF; Hsieh MY; Wang LY; Tsai JF; Wen-Yu ; Yu ML
Clin Ther; 2006 Dec; 28(12):2081-92. PubMed ID: 17296464
[TBL] [Abstract][Full Text] [Related]
25. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Chen DS; Kao JH
Antivir Ther; 2009; 14(2):203-10. PubMed ID: 19430095
[TBL] [Abstract][Full Text] [Related]
26. [Therapeutic efficacy of lamivudine in patients with hepatitis B virus-related decompensated cirrhosis in Korea].
Jung S; Suh DJ; Park HJ; Park YH; Song HG; Lee HC; Chung YH; Lee YS
Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):418-27. PubMed ID: 12506246
[TBL] [Abstract][Full Text] [Related]
27. Role of hepatitis B virus genotype mixture, subgenotypes C2 and B2 on hepatocellular carcinoma: compared with chronic hepatitis B and asymptomatic carrier state in the same area.
Yin J; Zhang H; Li C; Gao C; He Y; Zhai Y; Zhang P; Xu L; Tan X; Chen J; Cheng S; Schaefer S; Cao G
Carcinogenesis; 2008 Sep; 29(9):1685-91. PubMed ID: 18192693
[TBL] [Abstract][Full Text] [Related]
28. [Correlation of HBV DNA level and viral breakthrough during lamivudine therapy for chronic hepatitis B].
Park HS; Lee DH; Heo J; Kim GH; Kang DH; Song GA; Cho M
Korean J Hepatol; 2006 Jun; 12(2):173-83. PubMed ID: 16804342
[TBL] [Abstract][Full Text] [Related]
29. [The discrepancy of HBsAg titre and HBV DNA in patients with chronic hepatitis B, HBV-related liver cirrhosis and hepatocellular carcinoma].
Pei YZ; Han T; Ma XY; Li Y; Xing J; Song ZL
Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):743-6. PubMed ID: 22409845
[TBL] [Abstract][Full Text] [Related]
30. A study on efficacy of lamivudine therapy in decompensated cirrhosis of liver due to chronic hepatitis B virus infection.
Sharma YR; Miah AR; Saha SK; Mohammed S; Rahman M; Roy PK; Hasan M
Nepal Med Coll J; 2004 Dec; 6(2):106-11. PubMed ID: 16295739
[TBL] [Abstract][Full Text] [Related]
31. Recent progress and new trends in the treatment of hepatitis B.
Alberti A; Brunetto MR; Colombo M; Craxì A
J Med Virol; 2002 Jul; 67(3):458-62. PubMed ID: 12116046
[TBL] [Abstract][Full Text] [Related]
32. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis.
Hann HW; Fontana RJ; Wright T; Everson G; Baker A; Schiff ER; Riely C; Anschuetz G; Gardner SD; Brown N; Griffiths D;
Liver Transpl; 2003 Jan; 9(1):49-56. PubMed ID: 12514773
[TBL] [Abstract][Full Text] [Related]
33. A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients.
Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Kao JH; Chen DS
Liver Int; 2008 Aug; 28(7):1034-41. PubMed ID: 18492018
[TBL] [Abstract][Full Text] [Related]
34. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China.
Yao GB; Zhu M; Cui ZY; Wang BE; Yao JL; Zeng MD
J Dig Dis; 2009 May; 10(2):131-7. PubMed ID: 19426396
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
[TBL] [Abstract][Full Text] [Related]
36. [Comparison of lamivudine-induced HBsAg loss rate according to age in children with chronic hepatitis B].
Kim JM; Choe BH; Chu MA; Cho SM
Korean J Hepatol; 2009 Jun; 15(2):168-78. PubMed ID: 19581769
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy of antiviral treatment on intrahepatic HBV DNA and histology in HBeAg -positive chronic hepatitis B patients].
Lu HY; Zhuang LW; Yu YY; Si CW; Zheng JJ; Chen XY; Han ZH; Chen Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Feb; 22(1):54-6. PubMed ID: 18414702
[TBL] [Abstract][Full Text] [Related]
38. Early response to lamivudine therapy in clinically non-cirrhotic chronic hepatitis B patients with decompensation.
Dai CY; Yu ML; Hsieh MY; Lee LP; Hou NJ; Huang JF; Chen SC; Lin ZY; Hsieh MY; Wang LY; Tsai JF; Chang WY; Chuang WL
Liver Int; 2007 Dec; 27(10):1364-70. PubMed ID: 17900250
[TBL] [Abstract][Full Text] [Related]
39. Profile, spectrum and significance of hepatitis B virus genotypes in chronic HBV-infected patients in Yunnan, China.
You J; Sriplung H; Chongsuvivatwong V; Geater A; Zhuang L; Huang JH; Chen HY; Yu L; Tang BZ
Hepatobiliary Pancreat Dis Int; 2008 Jun; 7(3):271-9. PubMed ID: 18522881
[TBL] [Abstract][Full Text] [Related]
40. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion.
Fung J; Lai CL; Tanaka Y; Mizokami M; Yuen J; Wong DK; Yuen MF
Am J Gastroenterol; 2009 Aug; 104(8):1940-6; quiz 1947. PubMed ID: 19455108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
